Meeting
2015 ASCO Annual Meeting
CTEP #8850: A phase I trial of riluzole and sorafenib in patients with advanced solid tumors.
Authors
Kristen Renee Spencer
Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Kristen Renee Spencer , Janice M. Mehnert , Antoinette R. Tan , Rebecca Anne Moss , Kelly Levinson , Mark N. Stein , Lien Huzzy , Michael P. Kane , Darlene Gibbon , John Joseph Wright , Joseph Aisner , Robert S. DiPaola , Suzie Chen , Yvonne Wen , James Goydos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
New Targets and New Technologies
Clinical Trial Registration Number
NCT01303341
Citation
J Clin Oncol 33, 2015 (suppl; abstr 11086)
DOI
10.1200/jco.2015.33.15_suppl.11086
Abstract #
11086
Poster Bd #
300
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma: Final results from the dose-finding phase I part of the IMMU-Target trial.
First Author: Lisa Zimmer
Poster
2019 ASCO Annual Meeting
Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors.
First Author: Dana Backlund Cardin
Poster
2018 ASCO Annual Meeting
A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
First Author: Filip Janku
Poster
2013 ASCO Annual Meeting
A phase I study of the combination of sorafenib (Sor) and bortezomib (Bor) in patients (pts) with metastatic melanoma (MM).
First Author: Ryan J. Sullivan